Apotex's Initial ANDA Submission for Ruxolitinib
Apotex filed its first Abbreviated New Drug Application (ANDA) for a generic version of ruxolitinib (Jakafi) on December 28, 2018, targeting the 15 mg strength. This was the earliest among challengers, positioning Apotex as a Paragraph IV filer under Hatch-Waxman, which triggered Incyte's 30-month stay on FDA approval.[1][2]
Key FDA Milestones and Paragraph IV Certifications
- October 2019: FDA accepted the ANDA for substantive review, listing it as first-to-file for several strengths (5 mg, 10 mg, 15 mg, 20 mg).
- Paragraph IV status confirmed: Apotex certified against all 24 Orange Book-listed patents for Jakafi, leading to patent litigation in the District of Delaware.[1][3]
Litigation Timeline Impacting Approval
- January 2019: Incyte sued Apotex shortly after submission, starting the 30-month stay (expiring June 28, 2021).
- August 2021: Court ruled in favor of Incyte on most patents (e.g., U.S. Patent Nos. 8,946,227 and 9,090,582), but invalidated one (9,816,690). Apotex appealed to the Federal Circuit.
- 2023-2024 updates: Federal Circuit affirmed key rulings in Incyte's favor in March 2024; Apotex's petitions for en banc review denied.[2][4]
Current Status and Tentative Approvals
Apotex received tentative approvals for multiple strengths:
- 5 mg, 10 mg, 15 mg: Tentatively approved July 2022.
- 20 mg and 25 mg: Tentatively approved later in 2022.
Final approval awaits 180-day exclusivity resolution (Apotex shares first-to-file status with a few others) and patent settlements. No final approval as of mid-2024; market entry likely post-2028 due to remaining pediatric exclusivity until February 2028.[1][5]
Comparison with Other Generic Challengers
| Company | First ANDA Filing | Tentative Approval Status | Litigation Outcome |
|---------------|-------------------|---------------------------|--------------------|
| Apotex | Dec 2018 | Yes (most strengths) | Mostly lost |
| MSN Labs | Feb 2019 | Yes | Ongoing |
| Sandoz | 2019 | Partial | Settled |
| Dr. Reddy's | 2020 | No | Lost key patents |
Apotex leads in filing date but faces delays from Incyte's strong patent portfolio.[2][3]
[1]: DrugPatentWatch.com - Ruxolitinib Patent Timeline
[2]: FDA Orange Book - Jakafi ANDA List
[3]: CourtListener - Incyte v. Apotex (Del. 1:19-cv-00119)
[4]: Federal Circuit - 2024 Ruling Summary
[5]: FDA Tentative Approval Notices for ANDA 213684